Last updated: 11/07/2018 12:40:51
Integrated analysis to estimate of the duration of protection provided by GSK’s hepatitis A and B vaccine Twinrix™ administered in healthy adults in a 0-1-6 schedule, based on the 20-year follow-up results of studies HAB-028 and HAB-032.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Integrated analysis to estimate of the duration of protection provided by GSK’s hepatitis A and B vaccine Twinrix™ administered in healthy adults in a 0-1-6 schedule, based on the 20-year follow-up results of studies HAB-028 and HAB-032.
Trial description: Integrated analysis to estimate of the duration of protection provided by GSK’s hepatitis A and B vaccine Twinrix™ administered in healthy adults in a 0-1-6 schedule, based on the 20-year follow-up results of studies HAB-028 and HAB-032.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
2016-01-06
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Van Damme P et al. (2017) Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine. Hum Vaccin Immunother. 13(5):972-980. doi: 10.1080/21645515.2016.1274473.
Medical condition
Hepatitis
Product
SB208127
Collaborators
Not applicable
Study date(s)
November 2015 to June 2016
Type
Not applicable
Phase
Not applicable
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
2016-01-06
Actual study completion date
2016-01-06
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website